Is BPC-157 legal in the United States?

BPC-157 is not FDA-approved, not on the pharmacy compounding list and banned in sport, and this guide explains each rule as of November 17, 2026.

Basics7 min read

Key takeaway

BPC-157 is not an FDA-approved drug and is not a component of any approved drug. FDA placed it in 503A compounding category 2 on September 29, 2023. After the nominations were withdrawn, FDA reviewed it on its own initiative, and at a July 23, 2026 advisory meeting FDA proposed not adding it to the 503A bulks list. WADA prohibits it at all times under S0. It does not appear on DEA's controlled substances list.

At a glance

Article typeBasics
Main guideBPC-157: complete guide
Regulatory statusNot FDA-approved“It's not an FDA-approved drug” (BPC-157: complete guide)
ClassTissue repair
Body systemsSkin & connective tissue, Gut, Muscle & bone, Heart & vessels
Studies cited0 in this article · 27 across 14 articles on BPC-157
ProductBPC-157 product page

Is BPC-157 legal in the United States? The answer depends on which rulebook you ask about. FDA approval, pharmacy compounding, controlled-substance law and sport anti-doping rules each treat it differently. This guide takes them one at a time, using FDA records, the Federal Register and the WADA list, checked on November 17, 2026.

Quick answer: BPC-157 is not a controlled substance under federal law, but it is not approved for any human use, and it is not on the list of substances pharmacies may use to compound drugs. FDA treats a product as a drug based on its intended use, so a "research use only" label does not protect a seller that markets BPC-157 for people. Athletes tested under WADA rules may not use it at any time.

This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.

Is BPC-157 an FDA-approved drug?

No. In its July 2026 review, FDA stated that there is no United States Pharmacopeia or National Formulary monograph for BPC-157 in either its free base or acetate form, and that neither form is a component of an FDA-approved drug (FDA presentation, July 23, 2026). FDA's briefing document adds that a search of approved products found no BPC-157 product approved in any country (FDA briefing document). The same document describes BPC-157, also called Bepecin or PL-14736, as a peptide reported to contain 15 amino acids.

For the published research on the compound itself, see our BPC-157 research guide.

What did FDA's 2023 category 2 listing mean?

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound with a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list (FDA). While FDA evaluates nominated substances, it sorts them into interim categories. Category 1 means under evaluation. Category 2 means the substance raises significant safety risks. Category 3 means nominated without adequate support (FDA category list).

FDA added BPC-157 to 503A category 2 on September 29, 2023 (FDA page, archived July 2025). FDA gave these reasons, which still appear on its current page:

  • Compounded drugs containing BPC-157 "may pose risk for immunogenicity for certain routes of administration."
  • They may have complexities with peptide-related impurities and active ingredient characterization.
  • FDA found "no, or only limited, safety-related information" and said it "lacks sufficient information to know whether the drug would cause harm when administered to humans."

FDA had questioned BPC-157 compounding before that. In an April 2020 warning letter to a compounding pharmacy, FDA said drugs it made with BPC-157 were not eligible for the 503A exemptions, because BPC-157 had no applicable monograph, was not a component of an approved drug and was not on the 503A bulks list. Our article on the 503A categories covers the wider framework.

Has BPC-157's compounding status changed since 2023?

Yes, but not in a way that opened compounding. FDA's current page lists BPC-157 among "bulk drug substances nominated but withdrawn," which it describes as substances "previously in category 2" whose nominations "were withdrawn by the nominators." FDA's category list updated May 14, 2026 no longer shows BPC-157 in category 2.

FDA then chose to evaluate BPC-157 free base and BPC-157 acetate "on its own initiative" for one proposed use, ulcerative colitis. It announced a Pharmacy Compounding Advisory Committee meeting in the Federal Register on April 16, 2026 (Docket FDA-2025-N-6895). At the meeting on July 23, 2026, FDA proposed that neither form be added to the 503A bulks list. FDA said the substances:

  • are not well characterized from a physicochemical perspective;
  • have limited information on historical use in compounding;
  • lack information on their safety profile and immunogenicity risks; and
  • have insufficient evidence of effectiveness for ulcerative colitis, a condition with several FDA-approved treatments.

The committee advises FDA; FDA makes the decision. FDA's meeting page listed no minutes or vote results when we checked on November 17, 2026, and we found no final FDA decision. As of that date, BPC-157 was not on the 503A bulks list (21 CFR 216.23).

Table 1

BPC-157 regulatory timeline

Date What happened
April 1, 2020 FDA warning letter says compounded BPC-157 drugs are not eligible for 503A exemptions
January 1, 2022 WADA's 2022 list takes effect, naming BPC-157 under S0
June 12, 2023 FDA warning letter to a seller of BPC-157 with "research purpose only" labels
September 29, 2023 FDA adds BPC-157 to 503A category 2
By April 2026 FDA lists BPC-157 as previously in category 2, nominations withdrawn
April 16, 2026 Federal Register notice of the advisory committee meeting
July 23, 2026 Advisory committee meets; FDA proposes not adding BPC-157 to the 503A bulks list
November 17, 2026 No final FDA decision found

Has FDA issued warning letters that mention BPC-157?

Yes. Besides the 2020 compounding letter, FDA sent a warning letter on June 12, 2023 to an online seller whose website took orders for BPC-157 and other products. The products carried "research purpose only" and "not for human consumption" statements. FDA wrote that evidence from the seller's website "establishes that your products are intended to be drugs for human use," and cited sections 505(a) and 301(d) of the Act, which prohibit introducing an unapproved new drug into interstate commerce. The letter quoted a health claim the seller made about BPC-157.

Is BPC-157 banned in sport?

Yes, for athletes under the World Anti-Doping Code. WADA's 2026 Prohibited List places BPC-157 under S0, non-approved substances. S0 covers any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use," and it is "prohibited at all times," in and out of competition. All substances in S0 are Specified Substances. WADA first named BPC-157 as an S0 example in its 2022 list, the first time any substance was named in that section.

WADA rules govern athletes under the World Anti-Doping Code and are separate from US drug law. See our guide to peptides on the 2026 WADA list.

Is BPC-157 a controlled substance?

Not under federal law. BPC-157 does not appear on the Drug Enforcement Administration's alphabetical list of controlled substances, in the edition dated November 12, 2026 (DEA). State laws can differ, and we have not surveyed them. Not being a controlled substance also does not make a product approved or lawful to sell as a drug. That question belongs to FDA.

What does research-use-only labeling mean, and not mean?

FDA's briefing document notes that websites offer BPC-157 products, including some labeled "for research purposes only and not for human or veterinary use." That label states the seller's intended use: laboratory research, not use in people or animals.

What the label does not do is decide the legal question by itself. FDA judges intended use by "objective intent," which can be shown by labeling claims, advertising, statements and the circumstances in which a product is sold (21 CFR 201.128). If the evidence shows a product is meant for people, FDA can treat it as an unapproved drug despite the label, as the 2023 letter shows. A research-use label also says nothing about safety in humans, which FDA says it lacks the information to judge.

Research-grade BPC-157 in our catalog is sold for laboratory research use only, not for human or veterinary use. For more, see what research use only means and are peptides legal in the USA.

Frequently asked questions about BPC-157 legality

Is BPC-157 FDA-approved?

No. It is not an approved drug and is not a component of any approved drug.

Can a compounding pharmacy make BPC-157?

Not under the 503A exemptions as of November 17, 2026. BPC-157 has no monograph, is not in an approved drug and is not on the 503A bulks list, and FDA proposed in July 2026 not to add it.

Did FDA remove BPC-157 from category 2?

FDA now lists it as previously in category 2, because the nominations were withdrawn. FDA then reviewed it on its own initiative and proposed not adding it to the 503A bulks list.

Is BPC-157 banned by WADA?

Yes. It is named under S0 and prohibited at all times for athletes subject to the World Anti-Doping Code.

Is BPC-157 a controlled substance?

No. It is not on DEA's federal list. State law may differ.

What to know now

  • FDA approval: none, in the US or, per FDA's search, any other country.
  • Compounding: category 2 from September 29, 2023; now listed as withdrawn; FDA proposed in July 2026 not to add it to the 503A bulks list.
  • Enforcement: FDA looks past research-use labels when the evidence shows a product is meant for people.
  • Sport: WADA S0, prohibited at all times.
  • Controlled substance: not on DEA's federal list.
  • Research grade: for laboratory research use only, not for human or veterinary use.

What we're watching

FDA's final decision on BPC-157 and the 503A bulks list after the July 2026 committee meeting, any minutes FDA posts from that meeting, and WADA's 2027 Prohibited List, which takes effect on January 1, 2027.

Also in the library

More for skin & connective tissue

All 23 compounds for skin & connective tissue

Sources: U.S. Food and Drug Administration 2026, Bulk drug substances used in compounding under section 503A of the FD&C Act; Code of Federal Regulations. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A . eCFR. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23; U.S. Food and Drug Administration 2026, Pharmacy Compounding Advisory Committee meeting: FDA presentations; U.S. Food and Drug Administration 2026, FDA briefing document: BPC-157-related bulk drug substances; U.S. Food and Drug Administration. (Updated 2026; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2025; Food and Drug Administration 2026, Federal Register; U.S. Food and Drug Administration 2026, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee; U.S. Food and Drug Administration 2020, Warning letter: Tailor Made Compounding LLC, MARCS-CMS 594743; U.S. Food and Drug Administration 2023, Warning letter: Warrior Labz SARMS, MARCS-CMS 655280; World Anti-Doping Agency 2026, The Prohibited List; World Anti-Doping Agency 2022, WADA's 2022 Prohibited List now in force; U.S. Drug Enforcement Administration 2026, Controlled substances: Alphabetical order; Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses" . eCFR. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128, 21 CFR 201.128: Meaning of "intended uses". All 15 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2026). Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  2. Code of Federal Regulations. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A. eCFR. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
  3. U.S. Food and Drug Administration. (2026, July 23). Pharmacy Compounding Advisory Committee meeting: FDA presentations. https://www.fda.gov/media/193773/download
  4. U.S. Food and Drug Administration. (2026). FDA briefing document: BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee, July 23-24, 2026. https://www.fda.gov/media/193343/download
  5. U.S. Food and Drug Administration. (Updated 2026, May 14). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/94155/download
  6. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  7. U.S. Food and Drug Administration. (2025). Certain bulk drug substances for use in compounding that may present significant safety risks (archived July 9, 2025, content current as of July 8, 2025). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" class="rw-link" target="_blank" rel="noopener noreferrer">https://web.archive.org/web/20250709193910/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. Food and Drug Administration. (2026, April 16). Pharmacy Compounding Advisory Committee; notice of meeting; establishment of a public docket; request for comments. Federal Register, Doc. 2026-07361. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
  9. U.S. Food and Drug Administration. (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  10. U.S. Food and Drug Administration. (2020, April 1). Warning letter: Tailor Made Compounding LLC, MARCS-CMS 594743. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020
  11. U.S. Food and Drug Administration. (2023, June 12). Warning letter: Warrior Labz SARMS, MARCS-CMS 655280. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023
  12. World Anti-Doping Agency. (2026). The Prohibited List. https://www.wada-ama.org/en/prohibited-list
  13. World Anti-Doping Agency. (2022). WADA's 2022 Prohibited List now in force. https://www.wada-ama.org/en/news/wadas-2022-prohibited-list-now-force
  14. U.S. Drug Enforcement Administration, Diversion Control Division. (2026, November 12). Controlled substances: Alphabetical order. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  15. Code of Federal Regulations. 21 CFR 201.128: Meaning of "intended uses". eCFR. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-E/section-201.128